



VACCINE ADMINISTRATION

Children ages 6 months to 11 years

FOR MORE INFO, VISIT [FDA.GOV](https://www.fda.gov) OR SCAN THE QR CODE PROVIDED



2 DOSES

Moderna
6 months - 5 years

1st Dose = 25 µg
(25 micrograms)

4 - 8 week waiting period

2nd Dose = 25 µg
(25 micrograms)

SIDE EFFECTS

- No deaths were reported in any trial participants
- Serious adverse events (SAE) rare overall
- No cases of myocarditis in any trial participants
- No cases of vaccine-associated anaphylaxis in any trial participants
- Pain at the injection site most common local reaction occurring within 7 days
- Fatigue and headache most common systemic reaction occurring within 7 days in children ages 2-5 years
- Irritability and sleepiness more common in children ages 6-23 month

TRIAL CONCLUSIONS

- Efficacy consistent with real-world vaccine effectiveness in all other age groups during Omicron predominance
- Antibody levels after 2 doses consistent with antibody levels after 2 doses in individuals ages 18-24 years
- Reactogenicity consistent with other recommended childhood vaccines

3 DOSES

Pfizer-BioNTech
6 months - 4 years

1st Dose = 3 µg
(3 micrograms)

3 - 8 week waiting period

2nd Dose = 3 µg
(3 micrograms)

8 week waiting period

3rd Dose = 3 µg
(3 micrograms)

SIDE EFFECTS

- No deaths were reported in any trial participants
- Serious adverse events (SAE) rare overall
- No cases of myocarditis in any trial participants
- No cases of vaccine-associated anaphylaxis in any trial participants
- Pain at the injection site most common local reaction occurring within 7 days
- Fatigue and headache most common systemic reaction occurring within 7 days in children ages 2-4 years
- Irritability and drowsiness more common in children ages 6-23 months

TRIAL CONCLUSIONS

- Efficacy estimates difficult to interpret given small numbers and limited follow-up time
- Antibody levels after 3 doses consistent with antibody levels after 2 doses in individuals ages 16-24 years
- Reactogenicity consistent with reactions seen in placebo recipients

3 DOSES

Pfizer-BioNTech
5 to 11 years

1st Dose = .2 mL
(.2 milliliters)

3 week waiting period

2nd Dose = .2 mL
(.2 milliliters)

5 month waiting period

Booster Dose = .2 mL
(.2 milliliters)

SIDE EFFECTS

Local reactions:

- Pain
- Redness
- Swelling

Systemic reactions:

- Tiredness
- Headache
- Muscle pain
- Chills
- Fever
- Nausea

CONTRAINDICATIONS for children with history of myocarditis or pericarditis

- If history is prior to COVID-19 vaccination, may receive Pfizer-BioNTech formulation for children 5 - 11 years of age after the episode of myocarditis or pericarditis has completely resolved.
- If myocarditis or pericarditis occurred after the first dose of an mRNA vaccine, experts advise no additional doses of any COVID-19 vaccine, including Pfizer-BioNTech formulation for children 5 through 11 years of age

People ages 6 months - 64 years, especially males ages 12 - 39 years, may consider getting the 2nd primary dose (Pfizer or Moderna) 8 weeks after the first dose. A longer interval between the 1st & 2nd primary doses may increase how much protection the vaccines offer & may further minimize the rare risk of heart problems, including myocarditis and pericarditis. [Stay Up to Date with Your COVID-19 Vaccines | CDC](https://www.cdc.gov/vaccines/imz/iqa/uptodate/)

